Deciphering molecular mechanisms of synergistic growth reduction in kinase inhibitor combinations
Authors:
- Eirini TsirvouliEirini Tsirvouli
- Henri Colyn BwanikaHBHenri Colyn Bwanika
- Ana Martinez del ValAna Martinez del Val
- Liv ThommesenLTLiv Thommesen
- Astrid LægreidAstrid Lægreid
- Martin KuiperMKMartin Kuiper
- Jesper OlsenJOJesper Olsen
- Åsmund FlobakÅsmund Flobak
Open Access
- 3 November 2026
- journal article
- Published by Elsevier in Molecular & Cellular Proteomics
Abstract
No abstract availableThis publication has 56 references indexed in Scilit:
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 updatePharmacological Research, 2025
- Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinomaTumour Virus Research, 2022
- eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK InhibitorsMolecular & Cellular Proteomics, 2022
- Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinomaCancer Letters, 2019
- Data Analysis2016
- Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitorsInvestigational New Drugs, 2014
- Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathwaysJournal of Surgical Research, 2013
- PI3K and MEK inhibitor combinations: examining the evidence in selected tumor typesCancer Chemotherapy and Pharmacology, 2013
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and ActivityCancer Cell, 2011
- Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription FactorCell, 1999